Cytokinetics (NASDAQ:CYTK) Given New $85.00 Price Target at Needham & Company LLC

Cytokinetics (NASDAQ:CYTK) had its price objective increased by equities researchers at Needham & Company LLC from $84.00 to $85.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target would indicate a potential upside of 21.26% from the stock’s current price.

A number of other research firms also recently weighed in on CYTK. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. Leerink Partners set a $83.00 target price on Cytokinetics in a research report on Monday, December 22nd. Citizens Jmp upped their price target on Cytokinetics from $88.00 to $96.00 and gave the company a “market outperform” rating in a research report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and set a $90.00 price objective on shares of Cytokinetics in a research note on Friday, January 9th. Finally, HC Wainwright lifted their price objective on Cytokinetics from $120.00 to $136.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Sixteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $88.78.

Cytokinetics Price Performance

CYTK opened at $70.10 on Wednesday. The company has a market capitalization of $8.57 billion, a P/E ratio of -11.14 and a beta of 0.54. The firm’s fifty day moving average price is $64.14 and its two-hundred day moving average price is $58.32. Cytokinetics has a fifty-two week low of $29.31 and a fifty-two week high of $70.98.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The firm had revenue of $17.76 million for the quarter, compared to the consensus estimate of $8.02 million. During the same period last year, the firm earned ($1.26) earnings per share. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. On average, equities research analysts expect that Cytokinetics will post -5.24 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Wendell Wierenga sold 20,000 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the transaction, the director directly owned 32,444 shares in the company, valued at $2,145,846.16. This represents a 38.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total transaction of $134,728.00. Following the sale, the executive vice president directly owned 138,552 shares of the company’s stock, valued at $8,484,924.48. This represents a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 151,385 shares of company stock valued at $9,817,158 over the last ninety days. Insiders own 3.40% of the company’s stock.

Institutional Trading of Cytokinetics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Cytokinetics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after acquiring an additional 191,336 shares during the period. State Street Corp raised its holdings in Cytokinetics by 3.7% in the fourth quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock worth $370,139,000 after purchasing an additional 207,961 shares during the period. Deep Track Capital LP raised its holdings in Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after purchasing an additional 650,000 shares during the period. Geode Capital Management LLC boosted its position in shares of Cytokinetics by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock worth $194,214,000 after purchasing an additional 15,815 shares in the last quarter. Finally, Vestal Point Capital LP grew its holdings in shares of Cytokinetics by 14.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock valued at $98,294,000 after buying an additional 384,469 shares during the period.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: MYQORZO approved in U.S., China and Europe; U.S. launch underway with first prescriptions dispensed within days — this turns near-term revenue into a tangible commercial story and is the biggest immediate catalyst. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue materially exceeded expectations: Q4 revenue ~$17.7M vs. consensus near $8M — suggests early commercial uptake or other revenue sources are ahead of models. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Strong balance sheet: company reported ~ $1.2 billion in cash, cash equivalents and investments as of 12/31/25 and provided 2026 financial guidance — gives runway to support commercialization and ongoing trials. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Near-term clinical catalyst: company expects to share ACACIA‑HCM topline results in Q2 2026 — a positive binary event that could drive further re-rating if favorable. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst views are mixed on CYTK’s near-term outlook — some focus on commercial upside while others remain cautious on uptake and margins. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK) and Tandem Diabetes Care (TNDM)
• Neutral Sentiment: Full earnings and call transcripts are available for details on commercialization plans and cost structure; useful for investors who want management tone and phasing. Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Small EPS miss and widening loss: GAAP EPS was -$1.50 vs. consensus -$1.48, and the loss increased versus prior year (-$1.26) — ongoing operating losses remain a drag until revenue scales. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.